

Complement inhibition as potential novel therapy for antibody-mediated rejection after lung transplantation in murine antibody-mediated rejection model.

Department of General Thoracic Surgery,
Chiba University Graduate School of Medicine

Yuki Shiina, Hidemi Suzuki, Taisuke Kaiho, Hiroki Matsumoto,
Atsushi Hata, Takayoshi Yamamoto, Kazuhisa Tanaka,
Yuichi Sakairi, Hironobu Wada, Takahiro Nakajima, Ichiro Yoshino



Relevant Financial Relationship Disclosure Statement


[Development of novel murine antibody mediated rejection model after orthotopic lung transplant.]
[Yuki Shiina]

I will not discuss off label use and investigational use of the **any drugs/devices**


No financial relationships exist related to this presentation

Anti-C5 (anti-complement 5)

- ✓ Antibody that binds to the C5 complement protein and blocks the terminal complement
- ✓ Anti-C5 had a potential benefit compared with standard of care in preventing acute AMR in recipients sensitized to their living-donor kidney transplants




William H, *Am J Transplant*, 2019



Montgomery, R. A. et al,
Am J Transplant. 2018


There are few reports which show the effectiveness of anti-C5 to **AMR after lung transplant.**

Method



Anti-C5 (40mg/kg), CyA:Cyclosporin A (10mg/kg), mPSL:Methylprednisolone (1.6mg/kg)


Pathological findings of graft left lung



CyA : Cyclosporin, mPSL:Methylprednisolone

Rejection scores (A) of left lung

DSA in serum



* : P value < 0.05, ** : P value < 0.01, CyA : Cyclosporin, mPSL: Methylprednisolone

Conclusion

- Anti-C5 therapy could be effective to prevent AMR among the mice orthotopic lung transplant model which was pre-sensitized by skin transplant.